A year after the Supreme Court's ruling in FTC v. Actavis, Inc., this article discusses fifteen ongoing cases that implicate "pay for delay" settlements in pharmaceutical patent litigation. It highlights key issues in dispute in each of these cases as the courts apply the "rule of reason" in novel and complex contexts.